An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment. is a phase 2, interventional study registered as NCT06855849 by Yonsei University, with a registry enrolment figure of 85 participants, started 2025-05 and due to reach its primary completion in 2027-05. Interventions recorded: Amivantamab + FOLFIRI. Conditions listed: RAS/BRAF Wild-type Advanced Colorectal Cancer Patients. Primary outcome: Overall Response Rate. Colorectal eligibility wording from the registry: "The participant must have been previously diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum". Sites: South Korea. No results are recorded here; the registry entry is the source.